MAP2K7 and Miyoshi myopathy: Similarly, over half of the patients with RAS-mutated MM treated with the MEK inhibitor trametinib experienced at least a 25% reduction in paraprotein although many responses were short lived, especially when the drugs were used as single agents [133].